Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

Temozolomide 4abemaciclib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2vorasidenib 1pembrolizumab 1Vorinostat 1Vincristine 1Specimen Handling 1Radiotherapy, Conformal 1Protons 1Proton Therapy 1Procarbazine 1OKN 007 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lomustine 1Irinotecan 1DNA Methylation 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Biopsy 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Oligodendroglioma × pembrolizumab × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡